Tofersen治疗SOD1-ALS的靶向蛋白质组学识别新型反应标志物
该研究对28例SOD1-ALS患者基线及tofersen治疗3、6、12个月后的脑脊液和血清进行120种神经、胶质和炎症标志物的纵向检测。结果显示部分蛋白在治疗3和6个月即响应,12个月时神经丝轻链、重链及NPTX家族成员水平仍低于基线并与临床反应相关,炎症标志物在12个月时显著升高。
要点
- Tofersen治疗3和6个月时脑脊液神经丝轻链、重链、Aβ1-40/42、NPY和UCHL1水平即出现响应。
- NPTX1、NPTX2和NPTXR不区分未治疗SOD1-ALS与对照,但对tofersen有响应。
- 治疗12个月时神经丝轻链、重链及NPTX家族成员水平仍低于基线且与临床反应相关。
核心结论
- 脑脊液生物标志物对tofersen治疗呈现复杂的时间依赖性差异响应,可能为SOD1-ALS临床试验提供更稳健的响应蛋白组合终点。
研究设计与样本
- 纵向研究,共纳入28例SOD1-ALS患者,在基线及tofersen治疗3、6、12个月时采集脑脊液和血清,检测120种神经、胶质和炎症标志物,并用常规方法验证。
主要发现
- 神经丝轻链、神经丝重链、淀粉样蛋白β1-40和β1-42、神经肽Y及泛素C末端水解酶L1的脑脊液水平在SOD1-ALS与对照组间存在差异,且在治疗3和6个月后对tofersen有响应。
- NPTX1、NPTX2和NPTXR不能区分未治疗SOD1-ALS与对照,但对tofersen有响应。
- 治疗12个月时神经丝轻链、神经丝重链、NPTX1、NPTX2和NPTXR水平仍低于基线,并与临床反应相关。
- 与脑脊液细胞增多和鞘内免疫球蛋白产生增加一致,炎症标志物在治疗12个月后显著升高。
临床怎么用
- 临床可关注脑脊液神经丝轻链、重链及NPTX家族成员作为tofersen治疗响应的潜在生物标志物。
- 治疗12个月时需注意炎症标志物升高,结合脑脊液细胞增多和鞘内免疫球蛋白产生增加进行解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofersen is the first effective and approved therapy for superoxide dismutase 1 (SOD1)-associated amyotrophic lateral sclerosis (ALS [SOD1-ALS]). Following treatment with tofersen, neurofilament levels in patients' cerebrospinal fluid (CSF) and serum seem to respond earlier than clinical parameters. This evidence prompted us to hypothesize that this novel treatment could provide an opportunity to identify additional biomarkers responsive to therapy in SOD1-ALS. METHODS: We investigated a panel of 120 neural, glial, and inflammatory markers in CSF and serum samples longitudinally collected from a total of 28 SOD1-ALS patients at baseline, and after 3, 6 and 12 months of treatment with tofersen, followed by validation with conventional methodology. RESULTS: We identified a set of proteins, including neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40 and amyloid-beta 1-42, neuropeptide Y (NPY), and ubiquitin C-terminal hydrolase L1 (UCHL1), whose CSF levels both differed between SOD1-ALS and the control group, and were responsive to tofersen at 3 and 6 months after treatment initiation. Another group of markers, including the neuropentraxin (NPTX) family members NPTX1, NPTX2 and NPTXR, did not separate untreated SOD1-ALS from controls, but was responsive to tofersen. At 12 months on tofersen the levels of neurofilament light chain, neurofilament heavy chain, NPTX1, NPTX2, and NPTXR remained reduced compared with baseline, and correlated with the clinical response to tofersen. Consistent with increasing CSF pleocytosis and intrathecal immunoglobulin production, inflammatory markers were significantly increased after 12 months of treatment. INTERPRETATION: Our results highlight a complex, time-dependent differential response of CSF biomarkers to tofersen treatment, and may pave the way for developing a panel of responsive proteins to make biomarker endpoints more robust in clinical trials for SOD1-ALS and beyond. ANN NEUROL 2025;98:1318-1334.
引用
- Steffke C, Baskar K, Bachhuber F, et al. Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis. Ann Neurol. 2025. PMID: 40781905. doi:10.1002/ana.70025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。